We reach more than 65,000 registered users in Dec!! Register Now
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model
- December 10, 2022
- 10 Views
- 0 Likes
- 0 Comment
Myriad’s MyRisk™ Hereditary Cancer test with RiskScore® provides a personalized breast cancer risk assessment for women of all ancestriesSALT LAKE CITY, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study validating RiskScore as a well-calibrated and more accurate predictor of breast cancer risk than a standard-of-care risk assessment alone. The data was shared in a spotlight
Cite This Article as
"Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model", MachPrinciple, December 10, 2022, https://machprinciple.com/post/Myriad-Genetics-Patient-Outcomes-Study-Shows-RiskScore-Leads-to-More-Accurate-Breast-Cancer-Risk-Prediction-than-Standard-of-Care-Risk-Model
No tags found for this post
